On December 11, 2016, on a sunny day, our company lit up lanterns and decorated them to welcome all members of the leadership team and the medical equipment team of Jiangsu Huihong International Group Medical and Health Products Import and Export Co., Ltd., and held a listing ceremony for the medical dressing production base. All employees of our company, leaders of Anji County, and relevant leaders of the development zone jointly attended the listing ceremony.
There are several key gene loci that require additional attention in the treatment of colorectal cancer (CRC). In addition to the RAS gene that affects the efficacy of drugs such as cetuximab and MSI/PD-L1 that affects immune therapy related indicators, HER2 gene abnormalities are also a common treatment entry point in colorectal cancer.
At the cellular level, a gene is equivalent to a point on a chromosome, called a locus. At the molecular level, a site can also be divided into many basic units, called seats. A locus generally refers to a nucleotide pair, and sometimes a mutation may occur when one of the bases changes.
The cure rate of late stage tumors is less than 20%, and if discovered in the first stage, the cure rate can reach as high as 95%. The reason why the mortality rate of cancer remains high is because it is found to be very difficult to treat in the middle and late stages. With the development of medicine, people have found the relationship between genes and tumors. Through gene examination, tumor indicators can be found, which can greatly improve the Lebensraum of patients.
Lung cancer is a malignant tumor that poses a serious threat to human health in the world today, and advances in molecular biology have greatly changed the treatment pattern of advanced NSCLC. The targeted treatment of lung cancer cannot be separated from molecular detection of lung cancer, which involves various aspects, and any factor may affect the accuracy of molecular detection results. In order to standardize the molecular detection of lung cancer, AZ collaborated with relevant domestic experts to comprehensively elaborate on the sample requirements, testing platform, testing treatment and standards, and testing concepts for molecular detection of lung cancer.